Ebselen - Sound Pharmaceuticals

Drug Profile

Ebselen - Sound Pharmaceuticals

Alternative Names: Ebselene; Ebseleno; Ebselenum; Harmokisane; PZ-51; SPI-1005; SPI-3005

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Nattermann; Sound Pharmaceuticals; University of Oxford
  • Class Antiulcers; Azoles; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar disorders; Hearing loss; Meniere's disease; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 10 Oct 2017 University of Oxford, Stanley Medical Research Institute and Sound Pharmaceuticals plans a phase II trial for Bipolar disorders in United Kingdom (PO) in October 2017 (NCT03013400) (EudraCT2015-000323-86)
  • 03 Oct 2017 Phase-II clinical trials in Meniere's disease in USA (PO)
  • 03 Oct 2017 Efficacy and adverse events data from a phase Ib/II trial in Meniere's disease released by Sound Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top